Morgan Stanley Sees Balance Sheet & Pipeline as More Critical for Johnson & Johnson

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating and $110.00 price target on Johnson & Johnson JNJ. In the report, Morgan Stanley noted, “Guidance confirmed 2015 will be a challenging year highlighted by pharma deceleration. Modest revenue improvement is encouraging, but performance may be tied to pharma pipeline visibility over biosimilar risk and balance sheet optionality. We remain EW.” Johnson & Johnson closed on Tuesday at $101.29.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsDavid R. LewisMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!